Lilly, Pfizer's pain data show mixed efficacy, safety issues by Nick Paul Taylor Friday, April 19, 2019 Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.
Pfizer, Lilly’s NGF painkiller meets endpoints in low back pain by Conor Hale Tuesday, February 19, 2019 Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.
Pfizer/Lilly NGF pain drug wins again, but safety issue lingers by Phil Taylor Tuesday, January 29, 2019 Pfizer and Lilly now have two trials showing NGF blocker tanezumab reduces pain in arthritis, but cases of rapid joint damage are still seen.
Pfizer/Lilly showcase data for NGF pain drug tanezumab at ACR by Phil Taylor Wednesday, October 24, 2018 Pfizer and Eli Lilly have inched closer to getting their NGF blocker tanezumab to the filing stage as an alternative to opioids for chronic pain.
